• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Fulvestrant-palbociclib and letrozole-palbociclib are equally effective for HR⁺ advanced breast cancer

byTeddy Guo
October 20, 2021
in StudyGraphics
Reading Time: 1 min read
0
Share on FacebookShare on Twitter

Click here to read this study in JAMA Oncology. 

RELATED REPORTS

Switching to camizestrant after ESR1 mutation detection prolongs progression free survival in advanced breast cancer

Vepdegestrant extends progression-free survival in ER-positive, HER2-negative breast cancer

Inavolisib lengthens progression-free survival time in HER2-negative advanced breast cancer

Tags: advanced breast cancerBreast Cancerfulvestranthormone receptor-positive breast cancerletrozoleLetrozole (Femara)palbociclibSelective estrogen receptor modulators
Previous Post

Nonnutritive sweeteners elicit more neural response to food cues compared to sugar

 Next Post

Adjuvant atezolizumab shows benefit in patients with stage II-IIIA non-small-cell lung cancer

RelatedReports

Preoperative bilateral breast imaging may reduce contralateral cancer recurrence
Endocrinology

Switching to camizestrant after ESR1 mutation detection prolongs progression free survival in advanced breast cancer

August 28, 2025
One-year of Herceptin preferable to two-year regimen
Endocrinology

Vepdegestrant extends progression-free survival in ER-positive, HER2-negative breast cancer

August 28, 2025
USPSTF recommends chemoprevention for women at high risk for breast cancer
Endocrinology

Inavolisib lengthens progression-free survival time in HER2-negative advanced breast cancer

August 26, 2025
Incidental findings common with breast imaging, often benign
Chronic Disease

Extended aromatase inhibitor therapy reduces breast cancer recurrence in postmenopausal women

August 21, 2025
Next Post
Lessons from real-world implementation of lung cancer screening

Adjuvant atezolizumab shows benefit in patients with stage II-IIIA non-small-cell lung cancer

Novel coronavirus identified from patients with pneumonia in Wuhan, China

Treatment of immune-mediated inflammatory diseases with tumor necrosis factor inhibitors is associated with lower COVID-19 hospitalization and death rates compared to other treatments

Working from home is the new normal as we combat the Covid-19

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Cardiopulmonary Point-of-Care Ultrasonography for Hospitalist Management of Undifferentiated Dyspnea
  • Efruxifermin improves fibrosis in patients with metabolic dysfunction-associated steatohepatitis
  • Measurement-Based Care to Enhance Antidepressant Treatment Outcomes in Major Depressive Disorder: A Randomized Clinical Trial
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.